clinical utility
Early Adopters Share Experiences With Grail Cancer Test as Firm Faces New Clinical Questions
Premium
Real-world and trial data shored up evidence that the company's multi-cancer detection assay can guide follow-up assessment of patients with a positive result.
The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.
Illumina, Henry Ford Health Partner on Genomic Testing for Cardiovascular Patients
The partnership could yield data to support the use of whole-genome sequencing in treating and managing cardiovascular disease, the leading cause of death in the US.
Stakeholders are working to harmonize strategies for overcoming the challenges faced by new blood-based multi-cancer early detection assays.
The diagnostics subsidiary, created by Oxford Nanopore Technologies last year, plans to forge partnerships with clinical and industry partners.